DanCann Pharma A/S (NGM:DANCAN)

Market Cap	2.53M
Revenue (ttm)	5.94M
Net Income (ttm)	-14.78M
Shares Out	3.99M
EPS (ttm)	-2.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,451
Average Volume	142,589
Open	0.5400
Previous Close	0.5450
Day's Range	0.4220 - 0.5400
52-Week Range	0.1430 - 18.8000
Beta	1.94
RSI	53.16
Earnings Date	Oct 27, 2025

About DanCann Pharma

DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company’s development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros. It is also involved in the import and distribution of Bedrocan CannGros, Bedica CannGros, and Bediol CannGros...

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Employees: 5
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: DANCAN

Financial Performance

In 2024, DanCann Pharma's revenue was 7.37 million, an increase of 3.06% compared to the previous year's 7.15 million. Losses were -8.35 million, -86.59% less than in 2023.

Financial numbers in DKK